Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research.

ABSTRACT: Cervical cancer is the fourth most lethal women's cancer worldwide. Current treatments against cervical cancer include surgery, radiotherapy, chemotherapy, and anti-angiogenic agents. However, despite the various treatments utilized for the treatment of cervical cancer, its disease burden remains a global issue. Persistent infection of human papillomavirus (HPV) has been identified as an essential step of pathogenesis of cervical cancer and many other cancers, and nation-wide HPV screening as well as preventative HPV vaccination program have been introduced globally. However, even though the commercially available prophylactic HPV vaccines, Gardasil (Merck) and Cervarix (GlaxoSmithKline), are effective in blocking the entry of HPV into the epithelium of cervix through generation of HPV-spe

SUBMITTER: Lee SJ 

PROVIDER: S-EPMC4944018 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature